In a bid to redefine chronic disease treatment, Tune Therapeutics employs a targeted epigenetic editing approach. A recent Longevity.Technology feature details how CSO Derek Jantz’s team uses the Tempo platform—combining dCas technology with effector proteins—to finely adjust gene expression. This illustrates a significant step in developing therapies for chronic hepatitis B and beyond. Examine the detailed workflow and potential broader applications.